S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
ARCA:AGE

AgeX Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume376,461 shs
Market Capitalization$68.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone510 871 4190
Employees17

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.73 million
Book Value($0.10) per share

Profitability

Net Income$-12,150,000.00
Net Margins-582.11%
Return on Equity-27,824.97%

Miscellaneous

Market Cap$68.97 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AgeX Therapeutics (ARCA:AGE) Frequently Asked Questions

What stocks does MarketBeat like better than AgeX Therapeutics?

Wall Street analysts have given AgeX Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AgeX Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of AgeX Therapeutics' key competitors?

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the following people:
  • Dr. Michael D. West, Founder, Pres, CEO & Director (Age 67, Pay $557.05k)
  • Dr. Nafees Naseer Malik M.D., Chief Operating Officer (Age 42, Pay $329.54k)
  • Ms. Andrea Eun-Jae Parks CPA, Chief Financial Officer
  • Dr. Ivan Labat, Chief Information Officer
  • Ms. Judith Segall, Sec. (Age 67)

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the ARCA under the ticker symbol "AGE."

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is AgeX Therapeutics?

AgeX Therapeutics has a market capitalization of $0.00 and generates $1.73 million in revenue each year. AgeX Therapeutics employs 17 workers across the globe.

What is AgeX Therapeutics' official website?

The official website for AgeX Therapeutics is www.agexinc.com.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The company can be reached via phone at 510 871 4190.

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.